Jason Mast / Endpoints
Link to story
Context
- Thrive Earlier Detection reports successful liquid biopsy testing for presymptomatic cancers in a trial with Geisinger (Kate Sheridan / STAT)
- Blood test for cancer detection company Grail rakes in $390M in latest round (Natalie Grover / Endpoints)